Scientific advisors

Vincenzo Cerundolo, PhD

SAB member

vincenzo

Vincenzo Cerundolo is Professor of Immunology and director of the MRC Human Immunology Unit of the University of Oxford. He has carried out important research in the field of processing and presentation of antigenic peptides and lipids to T cells, and on the role of tumour-specific T lymphocytes in cancer immunity. Professor Cerundolo is currently studying the cross-talk between innate and adaptive immune responses required for optimal expansion and activation of tumour-specific T cells.

 

Hans Wigzell, PhD

SAB member

hans

Hans Wigzell is Professor Emeritus of Immunology. He holds both M.D. and D.Sc. degrees and is an elected member of the Royal Swedish Academy of Sciences, the Royal Swedish Academy of Engineering Sciences, the Finnish Society of Sciences and Letters, the Danish Academy of Sciences and Letters, EMBO and Academia Europea. Professor Wigzell is an honorary member of the American Society for Immunology, has received numerous awards and honorary doctorate degrees and published over 700 international peer reviewed articles. Professor Wigzell has been Vice Chancellor at Karolinska Institut, Scientific Advisor to the Swedish government, chairman of the Nobel Committee and the Nobel Assembly. Hans Wigzell is a board member of SOBI AB, Raysearch Labs AB, Valneva SA, Sarepta Therapeutics Inc, and Karolinska development AB.

  

Raj Mehta, PhD

SAB member

raj

Raj Mehta has over 15 years’ experience in identifying, nurturing and partnering early stage technologies in Biotech and Pharma Industry. At Cancer Research Technology (CRT), Raj has led portfolio management and commercialization of a range of oncology focused therapeutic and diagnostic assets. He led formation and has been Director of BliNK Therapeutics. At present, Raj is also interim CEO and Director of Revitope Ltd. Prior to joining CRT, he was Group Leader in the E. Merck Laboratory at MRC Collaborative Centre (London) leading groups supporting anti-angiogenesis and cardiovascular drug discovery projects for Merck KGaA (Darmstadt).